References
- Hu CM, Chang ZF. Mitotic control of dTTP pool: a necessity or coincidence?. J Biomed Sci. 2007; 14: 491–7
- Al-Madhoun AS, Tjarks W, Eriksson S. The role of thymidine kinases in the activation of pyrimidine nucleoside analogues. Mini Rev Med Chem. 2004; 4: 341–50
- Wu C, Yang R, Zhou J, Bao S, Zou L, Zhang P, et al. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods. 2003; 277: 157–69
- Gowda A, Byrd JC. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol. 2006; 13: 266–72
- Madewell BR. Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma. J Vet Intern Med. 2004; 18: 595–6
- Di RF, Giustolisi R, Lerner S, Cacciola E, O'Brien S, Kantarjian H, et al. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001; 12: 621–5
- Schwartz MK. Enzymes as prognostic markers and therapeutic indicators in patients with cancer. Clin Chim Acta. 1992; 206: 77–82
- O'Neill KL, Zhang F, Li H, Fuja DG, Murray BK. Thymidine kinase 1—a prognostic and diagnostic indicator in ALL and AML patients. Leukemia. 2007; 21: 560–3
- Zhang J, Jia Q, Zou S, Zhang P, Zhang X, Skog S, et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep. 2006; 15: 455–61
- Fujiwaki R, Hata K, Moriyama M, Iwanari O, Katabuchi H, Okamura H, et al. Clinical value of thymidine kinase in patients with cervical carcinoma. Oncology. 2001; 61: 47–54
- Socialstyrelsen. Statistics Health and Diseases. 2003:6, Cancer incidence in Sweden. http://www.socialstyrelsen.se/NR/rdonlyres/8D37532A-BC53-4B38-9F06-73CD8BC5AD62/967/2003426.pdf.
- Cancer incidence in five continents. Volume VIII. IARC Sci Publ. 2002:1–781.
- Rosén M, Lundin A, Nyström L, Rutqvist L, Stenbeck M, Talbäck M. Incidens och dödlighet i bröstcancer under 25 år. Internationella och regionala jämförelser. Läkartidningen. 2000; 97: 294–99
- Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet. 2000; 355: 1822
- Dobrovolsky VN, Bucci T, Heflich RH, Desjardins J, Richardson FC. Mice deficient for cytosolic thymidine kinase gene develop fatal kidney disease. Mol Genet Metab. 2003; 78: 1–10
- Bello LJ. Regulation of thymidine kinase synthesis in human cells. Exp Cell Res. 1974; 89: 263–74
- Chang ZF, Huang DY, Lai TC. Different regulation of the human thymidine kinase promotor in normal human diploid IMR-90 fibroblasts and HeLa cells. J Biol Chem. 1995; 270: 27374–9
- Munch-Petersen, B, Cloos, L, Jensen, HK, Tyrsted, G, Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul. 1995;35:69–89.
- Roehl HH, Conrad SE. Identification of a G1-S-phase-regulated region in the human thymidine kinase gene promotor. Mol Cell Biol. 1990; 10: 3834–7
- Käpyaho K, Tanner P, Weber T. Effect of complement binding on a solid-phase immunometric TSH assay. Scand J Clin Lab Invest. 1989; 49: 211–5
- Carlander D, Larsson A. Avian antibodies can eliminate interference due to complement activation in ELISA. Ups J Med Sci. 2001; 106: 189–95
- Larsson A, Karlsson-Parra A, Sjoquist J. Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid factors. Clin Chem. 1991; 37: 411–4
- Larsson A, Sjoquist J. Chicken IgY: utilizing the evolutionary difference. Comp Immunol Microbiol Infect Dis. 1990; 13: 199–201
- Larsson A, Mellstedt H. Chicken antibodies: a tool to avoid interference by human anti-mouse antibodies in ELISA after in vivo treatment with murine monoclonal antibodies. Hybridoma. 1992; 11: 33–9